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Abstract
Low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglycerides, and total cholesterol are heritable, modifiable, risk factors for coronary artery 
disease. To identify new loci and refine known loci influencing these lipids, we examined 188,578 
individuals using genome-wide and custom genotyping arrays. We identify and annotate 157 loci 
associated with lipid levels at P < 5×10−8, including 62 loci not previously associated with lipid 
levels in humans. Using dense genotyping in individuals of European, East Asian, South Asian, 
and African ancestry, we narrow association signals in 12 loci. We find that loci associated with 
blood lipids are often associated with cardiovascular and metabolic traits including coronary artery 
disease, type 2 diabetes, blood pressure, waist-hip ratio, and body mass index. Our results 
illustrate the value of genetic data from individuals of diverse ancestries and provide insights into 
biological mechanisms regulating blood lipids to guide future genetic, biological, and therapeutic 
research.
Introduction
Blood lipids are heritable, modifiable, risk factors for coronary artery disease (CAD)1,2, a 
leading cause of death3. Human genetic studies of lipid levels can identify targets for new 
therapies for cholesterol management and prevention of heart disease, and can complement 
animal studies4,5. Studies of naturally occurring genetic variation can proceed through large-
scale association analyses focused on unrelated individuals or through investigation of 
Mendelian forms of dyslipidemia in families6. We previously identified 95 loci associated 
with blood lipids, accounting for ~10-12% of the total trait variance4 and showed that 
variants with small effects can point to pathways and therapeutic targets that enable 
clinically-important changes in blood lipids4,7.
Here, we report on studies of naturally occurring variation in 188,578 European-ancestry 
individuals and 7,898 non-European ancestry individuals. Our analyses identify 157 loci 
associated with lipid levels at P < 5×10−8, including 62 new loci. Thirty of the 62 loci do not 
include genes implicated in lipid biology by previous literature. We tested lipid-associated 
SNPs for association with mRNA expression levels, carried out pathway analyses to uncover 
relationships between loci, and compared the locations of lipid-associated SNPs with those 
of genes and other functional elements in the genome. These results provide direction for 
biological and therapeutic research into risk factors for CAD.
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Results
Novel loci associated with blood lipid levels
We examined subjects of European ancestry, including 94,595 individuals from 23 studies 
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genotyped with GWAS arrays4 and 93,982 individuals from 37 studies genotyped with the 
Metabochip array8 (Supplementary Table 1 and Supplementary Fig. 1). The Metabochip 
includes variants representing promising loci from our previous GWAS (14,886 SNPs) and 
from GWAS of other CAD risk factors and related traits (50,459 SNPs), variants from the 
1000 Genomes Project9 and focused resequencing10 efforts in 64 previously associated loci 
(28,923 SNPs), and fine-mapping variants in 181 loci associated with other traits (93,308 
SNPs). In cases where Metabochip and GWAS array data were available for the same 
individuals, we used Metabochip data to ensure key variants were directly genotyped, rather 
than imputed.
We excluded individuals known to be on lipid lowering medications and evaluated the 
additive effects of each SNP on blood lipid levels after adjusting for age and sex. Genomic 
control values11 for the initial meta-analyses were 1.10 – 1.15, low for a sample of this size, 
indicating that population stratification should have only a minor impact on our results 
(Supplementary Fig. 2). After genomic control correction, 157 loci associated with blood 
lipid levels were identified (P < 5×10−8), including 62 new loci (Tables 1A-D, Figure 1, 
Supplementary Tables 2 and 3). Loci were >1 Mb apart and nearly independent (r2 < 0.10). 
Of the 62 novel loci, 24 demonstrated the strongest evidence of association with HDL 
cholesterol, 15 with LDL cholesterol, 8 with triglyceride levels, and 15 with total cholesterol 
(Supplementary Fig. 3). Several of these loci were validated by a similar extension based on 
GLGC GWAS results 12.
The effects of newly identified loci were generally smaller than in earlier GWAS 
(Supplementary Fig. 4). For the 62 newly identified variants, trait variance explained in the 
Framingham offspring were 1.6% for HDL cholesterol, 2.1% for triglycerides, 2.4% for 
LDL cholesterol, and 2.6% for total cholesterol.
Overlap of genetic discoveries and prior knowledge
To investigate connections between our new loci and known lipid biology, we first 
catalogued genes within 100 kb of the peak associated SNPs and searched PubMed and 
OMIM for occurrences of these gene names and their aliases in the context of relevant 
keywords. After manual curation, we identified at least one strong candidate in 32 of the 62 
loci (52%) (Supplementary Table 4). For the remaining 30 loci, we found no literature 
support for the role of a nearby gene on blood lipid levels. This search highlighted genes 
whose connections to lipid metabolism have been extensively documented in mouse models 
(such as VLDLR13 and LRPAP113) and human cell lines (such as VIM14), as well as 
candidates whose connection to lipid levels is more recent, such as VEGFA. For the latter, 
recent studies of VEGFB have suggested that vascular endothelial growth factors have an 
unexpected role in the targeting of lipids to peripheral tissues15, which we corroborate by 
associating variants near VEGFA with blood triglyceride and HDL levels.
Multiple types of evidence supported several literature candidates (Supplementary Table 2). 
For example, VLDLR is categorized by Gene Ontology16 in the retinoid × nuclear receptor 
(RXR) activation pathway, which also includes genes (APOB, APOE, CYP7A1, APOA1, 
HNF1A, HNF4A) in previously implicated loci4. However, since these additional sources of 
evidence build on overlapping knowledge they are not truly independent.
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To estimate the probability of finding ≥32 literature supported candidates after automated 
search and manual review of results, we repeated our text-mining literature search using 100 
permutations of SNPs matched for allele frequency, distance to the nearest gene, and 
number of linkage disequilibrium proxies. To approximate hand-curation of the text-mining 
results, we focused on genes implicated by 3 or more publications (25 in observed data, 8.7 
on average in control SNP sets, P = 8×10−8).
Pathway analyses
We performed a gene-set enrichment analysis, using MAGENTA17, to evaluate over-
representation of biological pathways among associated loci. Across the 157 loci, 
MAGENTA identified 71 enriched pathways. These pathways included at least one gene in 
20 of our newly identified loci (Supplementary Table 5). Examples include DAGLB 
(connected to previously associated loci by genes in the triglyceride lipase activity pathway), 
INSIG2 (connected by the cholesterol and steroid metabolic process pathways), AKR1C4 
(connected by the steroid metabolic process and bile acid biosynthesis pathways), VLDLR 
(connected by the retinoic × receptor activation and lipid transport pathways, among others), 
PPARA, ABCB11, and UGT1A1 (three genes assigned to pathways implicated in activation 
of nuclear hormone receptors, which play an important role in lipid metabolism through the 
transcriptional regulation of genes in sterol metabolic pathways18). Among the 16 loci 
where literature review and pathway analysis both suggested a candidate, the predictions 
overlapped 14 times (Supplementary Table 2; by chance, we expect 6.6 overlapping 
predictions, P = 1×10−5).
Protein-protein interactions
We assessed evidence for physical interactions between proteins encoded near our 
associated SNPs using DAPPLE19. We found an excess of direct protein-protein interactions 
for genes in loci associated with LDL (10 interactions, P = 0.0002), HDL (8 interactions, P 
= 0.002), and total cholesterol (6 interactions, P = 0.017), but not for triglycerides (2 
interactions, P = 0.27) (Supplementary Fig. 5). Most of the interactions involved genes at 
known loci (such as the interaction network connecting PLTP, APOE, APOB, and LIPC) or 
highlighted the same genes as literature and pathway analyses (such as those connecting 
VLDLR, APOE, APOB, CETP, and LPL). Among novel loci, we identified a link between 
AKT1 and GSK3B. GSK3B has been shown to play a role in energy metabolism20 and its 
activity is regulated by AKT1 through phosphorylation21. Literature review also supported a 
role in blood lipid levels for these two genes.
Regulation of gene expression by associated variants
Many complex trait associated variants act through the regulation of gene expression. We 
examined whether our 62 novel variants were associated with expression levels of nearby 
genes in liver, omental fat, or subcutaneous fat. Fifteen were associated with expression of a 
nearby transcript with P < 5×10−8 (Supplementary Table 6) and, in seven, the lipid-
associated variant was in strong disequilibrium with the strongest expression-quantitative 
trait locus (eQTL) for the region (r2 > 0.8). In three of these loci, literature search also 
prioritized candidate genes. In all three, eQTL analysis and literature review identified the 
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same candidate (DAGLB, SPTLC3, and PXK, P = 0.05). For the remaining four loci (near 
RBM5, ADH5, TMEM176A, and GPR146), analysis of expression levels identified 
candidates that were not supported by literature or pathway analyses.
Coding variation
In some loci where previous coding variant association studies were inconclusive, we now 
find convincing evidence of association, demonstrating the benefits of the large sample sizes 
achievable by collaboration. For example, in the APOH locus22, our most strongly 
associated variant is rs1801689 (APOH C325G, P = 1×10−11 for LDL cholesterol). Overall, 
at 15 of the 62 new loci, there is at least one nonsynonymous variant within 100kb and in 
strong (r2>0.8) linkage disequilibrium with the index SNP (Supplementary Table 7)(18 loci 
with no restrictions on distance). This ~30% overlap between associated loci and coding 
variation is similar to that in other complex traits9. Unexpectedly, in the 11 loci where a 
candidate was suggested by literature review and by coding variation, the two coincided 
seven times (P = 0.03 compared to expected chance overlap of 3.8 times); thus, agreement 
between literature and coding variation was less significant than for eQTL and pathway 
analysis or protein-protein interactions.
Overlap between association signals and regulators of transcription in liver
Despite our efforts, 18 of the 62 new loci remain without prioritized candidate genes. The 
liver is an important hub of lipid biosynthesis and there is evidence that lipid loci might be 
associated with changes in gene regulation in liver cells23. Using ENCODE data23, we 
evaluated whether associated SNPs overlapped experimentally annotated functional 
elements identified in HepG2 cells, a commonly used model of human hepatocytes. To 
determine significance, we generated 100,000 lists of permuted SNPs, matched for minor 
allele frequency, distance to the nearest gene, and number of SNPs in r2 > 0.8 (described in 
Methods). In HepG2 cells, lipid-associated SNPs were enriched in eight of the 15 functional 
chromatin states defined by Ernst et al.24 (P < 1×10−5; Supplementary Table 8). The 
strongest enrichment was in regions with “strong enhancer activity” (3.7-fold enrichment, P 
= 2×10−25; Supplementary Table 9). In the other eight cell types examined by Ernst et al., 
no more than three functional chromatin states showed evidence for enrichment (and, when 
present, enrichment was weaker).
We proceeded to investigate the overlap between lipid loci and functional marks in HepG2 
cells in more detail (Supplementary Table 9). Notable regulatory elements showing 
significant overlap with lipid loci included histone marks associated with active regulatory 
regions (H3K27ac, P = 3×10−20; H3K9ac, P = 3×10−22), promoters (H3K4me3, P = 
2×10−15, H3K4me2, P = 8×10−12), transcribed regions (H3K36me3, P = 4×10−14), 
indicators of open chromatin (FAIRE, P = 5×10−9; DNase, P = 2×10−4), and regions that 
interact with transcription factors HNF4A (P = 6×10−10) and CEBP/B (P = 1×10−5). 
Overall, 56 of our 62 new loci contained at least one SNP that overlaps a functional mark24 
and/or chromatin state23 highlighted in Supplementary Table 9, including all but 3 of the 
loci where no candidates were suggested by literature review or analyses of pathways, 
coding variation, or gene expression (Supplementary Table 10).
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Initial fine-mapping of 65 lipid-associated loci
Previous fine-mapping of five LDL-associated lipid loci found that variants showing the 
strongest association were often substantially different in frequency and effect size from 
those identified in GWAS10. Metabochip genotypes enabled us to carry out an initial fine-
mapping analysis for 65 loci: 60 selected for fine-mapping based on our previous study4 and 
5 nominated for fine-mapping because of association to other traits.
For each of these loci, we identified the most strongly associated Metabochip variant and 
evaluated whether it (a) reached genome-wide significant evidence for association (to avoid 
chance fluctuations in regions where the signal was relatively weak) and (b) was different 
from the GWAS index SNP in terms of frequency and effect size (operationalized to r2 < 0.8 
with the GWAS index SNP). In the European samples, fine-mapping identified eight loci 
where the fine-mapping signal was clearly different from the GWAS signal (Supplementary 
Table 11). The two largest differences were at the loci near PCSK9 (top GWAS variant with 
minor allele frequency f = 0.24 and P = 9×10−24; fine-mapping variant with f = 0.03, P = 
2×10−136) and APOE (GWAS variant f = 0.20, P = 3×10−44, fine-mapping variant f = 0.07, 
P = 3×10−651), consistent with Sanna et al10. Large differences were also observed near 
LRP4 (GWAS f = 0.17, P = 8×10−14; fine-mapping f = 0.35, P = 1×10−26), IGF2R (GWAS 
f = 0.16, P = 7×10−9; fine-mapping f = 0.37, P = 2×10−13), NPC1L1 (GWAS f = 0.27, P = 
2×10−5; fine-mapping f = 0.24, P = 1×10−12), ST3GAL4 (GWAS f = 0.26, P = 2×10−6; fine-
mapping f = 0.07, P = 6×10−11), MED1 (GWAS f = 0.37, P = 3×10−5; fine-mapping f = 
0.24, P = 2×10−10), and COBLL1 (GWAS f = 0.12, P = 2×10−6; fine-mapping f = 0.11, P = 
6×10−9). Thus, although the large changes observed by Sanna et al10 after fine-mapping are 
by no means unique, they are not typical. Except for the R46L variant in PCSK9, the 
variants showing strongest association in fine-mapped loci all had minor allele frequency > .
05.
We also attempted fine-mapping in African (N=3,263), East Asian (N=1,771), and South 
Asian (N=4,901) ancestry samples. Despite comparatively small samples, ancestry-specific 
analyses identified SNPs clearly distinct from the original GWAS variant in five loci 
(Supplementary Table 11). These were: APOE, consistent with European ancestry analyses 
above; three loci where differences in linkage disequilibrium between populations enabled 
fine-mapping in African (SORT1, LDLR) or East Asian (APOA5) ancestry samples; and 
CETP, where an African-specific variant was present. For CETP, SORT1, and APOA5, 
results are consistent with other fine-mapping and functional studies7,7,25,26.
Association of lipid loci with metabolic and cardiovascular traits
To evaluate the role of the 157 loci identified here on related traits, we evaluated the most 
strongly associated SNPs for each locus in genetic studies of coronary artery disease (CAD, 
N=114,590 including 37,653 cases)27,28, type 2 diabetes (T2D, N=47,117 including 8,130 
cases)29, body mass index (BMI, N=123,865 individuals)30 and waist-hip ratio (WHR, 
N=77,167 individuals)31, systolic and diastolic blood pressure (SBP and DBP, N=69,395 
individuals)32, and fasting glucose (N=46,186 non-diabetics)33. We observed an excess of 
SNPs nominally associated (P < 0.05) with all these traits: a 5.1 fold excess for CAD (40 
nominally significant loci, P = 2×10−19), a 4.1 fold excess for BMI (32 loci, P = 1×10−11), 
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3.7 fold excesses for DBP (29 loci, P = 1×10−9), a 3.4 fold excess for WHR (27 loci, P = 
1×10−9), a 2.5 fold excess for SBP (20 loci, P = 1×10−4), a 2.3 fold excess for T2D (18 loci, 
P = 0.001), and a 2.2 fold excess for fasting glucose (17 loci, P = 3×10−3) (Supplementary 
Table 12). Interestingly, among the novel loci, we observed greater overlap with BMI, SBP, 
and DBP (9 overlapping loci each) than with CAD (8 overlapping loci). Among new loci, 
the two SNPs showing strongest association to CAD map near RBM5 (rs2013208, PHDL = 
9×10−12, PCAD = 7×10−5) and CMTM6 (rs7640978, PLDL = 1×10−8, PCAD = 4×10−4).
We tested whether the LDL-, total cholesterol- or triglyceride-increasing allele, or HDL-
decreasing allele was associated with increased risk of cardiovascular disease or related 
metabolic outcomes; the direction of effect of each locus was categorized according to the 
primary association signal at the locus, as in Tables 1A-D. We observed association with 
increased CAD risk (104/149, P = 1×10−6), SBP (96/155, P = 2.7×10−3) and WHR adjusted 
for BMI (92/154, P = 0.019). There were many instances where a single locus was 
associated with many traits. These included variants near FTO, consistent with previous 
reports34; near VEGFA (associated with triglyceride levels, CAD, T2D, SBP, and DBP), 
near SLC39A8 (associated with HDL cholesterol, BMI, SBP, and DBP), and near MIR581 
(associated with HDL cholesterol, BMI, T2D, and DBP). In some cases, like FTO, a strong 
association with BMI or another phenotype generates weaker association signals for other 
metabolic traits34. In other cases, like SORT1, a primary effect on lipid levels may mediate 
secondary association with other traits, like CAD7.
Association of individual lipids with coronary artery disease
Epidemiological studies consistently show high total cholesterol and LDL cholesterol levels 
are associated with increased risk of CAD, whereas high HDL cholesterol levels are 
associated with reduced risk of CAD35. In genetic studies, the connection between LDL 
cholesterol and CAD is clear, whereas the results for HDL cholesterol levels are more 
equivocal36-38. In our data, trait increasing alleles at the loci showing strongest association 
with LDL cholesterol (31 loci), triglycerides (30 loci), or total cholesterol (38 loci) were 
associated with increased risk of CAD (P = 2×10−12, P = 2×10−16, and P = 0.006). 
Conversely, trait decreasing alleles at loci showing the strongest association with HDL 
cholesterol (64 loci), were associated with increased CAD risk with P = 0.02. When we 
focused on loci uniquely associated with LDL cholesterol (12 loci where P > .05 for other 
lipids), triglycerides (6 loci), or HDL cholesterol (14 loci), only the LDL association 
remained significant (P = 0.03).
To better explore how associations with individual lipid levels related to CAD risk, we used 
linear regression to test whether association with lipid levels could predict impact on CAD 
risk. In this analysis, the effect on CAD of 149 lipid loci (CAD results were not available for 
8 SNPs) was correlated with LDL (Pearson r=0.74, P = 7×10−6) and triglyceride (Pearson 
r=0.46, P = 0.02) effect sizes, but not HDL effect sizes (Pearson r=−9×10−4, P = 0.99; 
Supplementary Fig. 6). Since most variants affect multiple lipid fractions (Figure 1), 
dissecting the relationship between lipid level and CAD effects requires multivariate 
analysis. In a companion manuscript, we use multivariate analysis and detailed examination 
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of triglyceride associated loci to show that increased LDL and triglyceride levels, but not 
HDL, appear causally related to CAD risk.
Evidence for additional loci, not yet reaching genome-wide significance
To evaluate evidence for loci not yet reaching genome-wide significance, we compared 
direction of effect in GWAS and Metabochip analyses of non-overlapping samples, outside 
the 157 genome-wide significant loci. Among independent variants (r2 < 0.1) with P < 0.1 in 
the GWAS-only analysis, a significant excess were concordant in direction of effect for 
HDL (62.9% in 1,847 SNPs, P < 10−16), LDL (58.6% of 1,730 SNPs, P < 10−16), 
triglyceride levels (59.1% of 1,783 SNPs, P < 10−16), and total cholesterol (61.0% of 1,904 
SNPs, P < 10−16), suggesting many additional loci to be discovered in future studies.
Discussion
Molecular understanding of the genes and pathways that modify blood lipid levels in 
humans will facilitate the design of new therapies for cardiovascular and metabolic disease. 
This understanding can be gained from studies of model organisms, in vitro experiments, 
bioinformatic analyses, and human genetic studies. Here, we demonstrate association 
between blood lipid levels and 62 new loci, bringing the total number of lipid-associated loci 
to 157 (See Tables 1A-D and Figure 1). All but one of the loci identified here include 
protein-coding genes within 100 kb of the SNP showing strongest association. While 38 of 
the 62 new loci include genes whose role in blood lipid levels is supported by literature 
review or analysis of curated pathway databases, the remainder includes only genes whose 
role on blood lipid levels has not been documented.
In total, there are 240 genes within 100 kb of one of our 62 new lipid-associated loci – 
providing a daunting challenge for future functional studies. Prioritizing on the basis of 
literature review, pathway analysis, regulation of mRNA expression levels, and protein 
altering variants suggests that 70 genes in 44 of the 62 new loci might be the focus of the 
first round of functional studies (summarized in Supplementary Table 2). While we found 
significant overlap, different sources of prioritization sometimes disagreed. This result 
suggests that truly understanding causality will be very challenging. The Supplementary 
Note includes an interpreted digest of genes highlighted by our study. Clearly, a range of 
approaches will be needed to follow-up these findings. To illustrate possibilities, consider U. 
S. Patent Application #20,090,036,394 disclosing that, in the mouse, knockout of Gpr146 
modifies blood lipid levels. Here, we show that variants near the human homologue of this 
gene, GPR146, are associated with levels of total cholesterol – providing an added incentive 
for studies of GPR146 inhibitors in humans. GPR146 encodes a G-protein coupled receptor 
– an attractive pharmaceutical target – so it is tempting to speculate that, one day, 
pharmaceutical inhibition of GPR146 may modify cholesterol levels and reduce risk of heart 
disease.
Each locus typically includes many strongly associated (and potentially causal) variants. Our 
fine-mapping results illustrate how genetic analysis of large samples and individuals of 
diverse ancestry can help focus the search for causal variants. In our fine-mapping analysis 
of 65 lipid-associated loci, we were able to separate the strongest signal in a region from the 
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prior GWAS signal in 12 instances. In three of these 12 instances, fine-mapping was enabled 
by analysis of a few thousand African or East Asian ancestry individuals, whereas in the 
remaining instances, fine-mapping was possible through examination of nearly 100,000 
European ancestry samples. A more detailed fine-mapping exercise, including imputation of 
variants from emerging very large reference panels, may help refine the location of 
additional signals.
Lipid-associated loci were strongly associated with CAD, T2D, BMI, SBP, and DBP. In 
univariate analyses, we found that impact on LDL and triglycerides all predicted association 
with CAD, but HDL did not. In a more detailed multivariate investigation, a companion 
manuscript shows that our data is consistent with the hypothesis that both LDL and 
triglycerides, but not HDL, are causally related to CAD risk. HDL, LDL, and triglycerides 
levels summarize aggregate levels of different lipid particles, each with potentially distinct 
consequences for CAD risk. We evaluated association of our loci with lipid subfractions in 
2,900 individuals from the Framingham Heart Study (Supplementary Table 13, 
Supplementary Fig. 7) and with sphingolipids, which are components of lipid membranes in 
cells, in 4,034 individuals from five samples of European ancestry39 (Supplementary Table 
14). The results suggest HDL-associated variants can have a markedly different impact on 
these sub-phenotypes. For example, among HDL loci, variants near LIPC were strongly 
associated with plasmalogen levels (P < 10−40), variants near ABCA1 were associated with 
sphingomyelin levels (P < 10−5), and variants near CETP – which show the strongest 
association with HDL cholesterol overall – were associated with neither of these. Detailed 
genetic dissection of these sub-phenotypes in larger samples, could lead to functional 
groupings of HDL-associated variants that reconcile the results of genetic studies (which 
show no clear connection between HDL cholesterol-associated variants and CAD risk) and 
epidemiologic studies (which show clear association between plasma HDL levels and CAD 
risk).
In summary, we report the largest genetic association study of blood lipid levels yet 
conducted. The large number of loci identified, the many candidate genes they contain, and 
the diverse proteins they encode generate new leads and insights into lipid biology. It is our 
hope that the next round of genetic studies will build on these results, using new sequencing, 
genotyping, and imputation technologies to examine rare loss-of-function alleles and other 
variants of clear functional impact to accelerate the translation of these leads into 
mechanistic insights and improved treatments for CAD.
Online Methods
Samples studied
We collected summary statistics for Metabochip SNPs from 45 studies. Among these, 37 
studies consisted primarily of individuals of European ancestry (see Supplementary Table 1 
and Supplementary Note for details), including both population-based studies and case-
control studies of CAD and T2D. Another 8 studies consisted primarily of individuals with 
non-European ancestry: two studies of South Asian descent, AIDHS/SDS (N=1,516) and 
PROMIS (N=3,385); two studies of East Asian descent, CLHNS (N=1,771) and TAI-CHI 
(N=7044); and five studies of recent African ancestry, MRC/UVRI GPC (N=1,687) from 
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Uganda, SEY (N=426) from the Caribbean, and FBPP (N=1,614, TG results unavailable), 
GXE (N=397), and SPT (N=838) from the United States (more details in Supplementary 
Table 1 and Supplementary Note).
Genotyping
We genotyped 196,710 genetic variants prioritized on the basis of prior GWAS for 
cardiovascular and metabolic phenotypes using the Illumina iSelect Metabochip8 
genotyping array. To design the Metabochip, we used our previous GWAS of ~100,000 
individuals4 to prioritize 5,023 SNPs for HDL cholesterol, 5,055 for LDL cholesterol, 5,056 
for triglycerides, and 938 for total cholesterol. These independent SNPs represent most loci 
with P < .005 in our original GWAS for HDL cholesterol, LDL cholesterol and triglycerides 
and with P < .0005 for total cholesterol. An additional 28,923 SNPs were selected for fine-
mapping of 65 previously identified lipid loci. The Metabochip also included 50,459 SNPs 
prioritized based on GWAS of non-lipid traits and 93,308 SNPs selected for fine-mapping of 
loci associated with non-lipid traits (5 of these loci were associated with blood lipids by the 
analyses described here).
Phenotypes
Blood lipid levels were typically measured after > 8 hours of fasting. Individuals known to 
be on lipid-lowering medication were excluded when possible. LDL cholesterol levels were 
directly measured in 10 studies (24% of total study individuals) and estimated using the 
Friedewald formula40 in the remaining studies. Trait residuals within each study cohort were 
adjusted for age, age2, and sex, and then quantile normalized. Explicit adjustments for 
population structure using principal component41 or mixed model approaches42 were carried 
out in 24 studies (35% of individuals); all studies were adjusted using genomic control prior 
to meta-analysis11. In studies ascertained on diabetes or CVD status, cases and controls were 
analyzed separately (Supplementary Table 1). All meta-analyses were limited to a single 
ancestral group (e.g. European only).
Primary statistical analysis
Individual SNP association tests were performed using linear regression with the inverse 
normal transformed trait values as the dependent variable and the expected allele count for 
each individual as the independent variable. These analyses were performed using PLINK 
(26 samples, 53% of the total number of individuals), SNPTEST (4 samples, 20% of 
individuals), EMMAX (9 samples, 14% of individuals), Merlin (4 samples, 9% of 
individuals), GENABEL (1 sample, 3% of individuals), and MMAP (1 sample, 1% of 
individuals) (Supplementary Table 1).
Meta-analysis
Meta-analysis was performed using the Stouffer method43,44, with weights proportional to 
the square root of the sample size for each sample. To correct for inflated test statistics due 
to potential population stratification, we first applied genomic control to each sample and 
then repeated the procedure with initial meta-analysis results. For GWAS samples, we used 
all available SNPs when estimating the median test statistic and inflation factor λ. For 
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Metabochip samples, we used a subset of SNPs (N = 7,168) that had P-values > 0.50 for all 
lipid traits in the original GWAS, expecting that the majority of these would not be 
associated with lipids and would behave as null variants in the Metabochip samples. Signals 
were considered to be novel if they reached a P-value < 5×10−8 in the combined GWAS and 
Metabochip meta-analysis and were >1 Mb away from the nearest previously described lipid 
locus and other novel loci. We used only European samples for the discovery of novel 
genome-wide significant loci. The non-European samples were meta-analyzed and 
examined only for fine-mapping analyses.
Quality control
To flag potentially erroneous analyses, we carried out a series of quality control steps. 
Average standard errors for association statistics from each study were plotted against study 
sample size to identify outlier studies. We inspected allele frequencies to ensure all analyses 
used the same strand assignment of alleles. We evaluated whether reported statistics and 
allelic effects were consistent with published findings for known loci. Genomic control 
values for study specific analyses were inspected, and all were <1.20. Finally, within each 
study, we excluded variants for which the minor allele was observed <7 times.
Proportion of trait variance explained
We estimated the increase in trait variance explained by novel loci in the Framingham 
cohort (N=7,132) using three models for each trait-residual: 1) lead and secondary SNPs 
from the previously published loci4 and 2) previously published lipid loci plus newly 
reported loci; and 3) newly reported loci. We regressed lipid residuals on these sets of SNPs 
using the lme kinship package in R.
Initial automated review of the published literature
An initial list of candidates within each locus was generated with Snipper (http://
csg.sph.umich.edu/boehnke/snipper/) and then subjected to manual review. For each locus, 
Snipper first generates a list of nearby genes and then checks for the co-occurrence of the 
corresponding gene names and selected search terms (“cholesterol”, “lipids”, “HDL”, 
“LDL”, or “triglycerides”) in published literature and OMIM. We supplemented this 
approach with traditional literature searches using PubMed and Google.
Generating permuted sets of non-associated SNPs
To estimate the expected chance overlap between literature searches and our loci, we 
generated lists of permuted SNPs. To generate these lists, we first identified all non-
associated lipid SNPs (P > 0.10 for any of the 4 lipid traits) and created bins based on 3 
statistics: minor allele frequency, distance to the nearest gene, and number of SNPs with r2 > 
0.8. For each index SNP, we identified 500 non lipid-associated SNPs that fell within the 
same 3 bins and randomly selected one SNP for each permuted list.
Pathway analyses
To investigate if lipid-associated variants overlapped previously annotated pathways, we 
used gene set enrichment analysis (GSEA), as implemented in MAGENTA17 using the 
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meta-analysis of all studies, including GWAS and Metabochip SNPs. Briefly, MAGENTA 
first assigns SNPs to a given gene when within 110 kb upstream or 40 kb downstream of 
transcript boundaries. The most significant SNP P-value within this interval is then adjusted 
for confounders (gene size, marker density, LD) to create a gene association score. When the 
same SNP is assigned to multiple genes, only the gene with the lowest score is kept for 
downstream analyses. Subsequently, MAGENTA attaches pathway terms to each gene using 
several annotation resources, including GO, PANTHER, Ingenuity, and KEGG. Finally, the 
genes are ranked on their gene association score, and a modified GSEA test is used to test 
the null hypothesis that all gene score ranks above a given rank cutoff are randomly 
distributed with regard to a given pathway term (and compared to multiple randomly 
sampled gene sets of identical size). We evaluated enrichment by using a rank cutoff of 5% 
of the total number of genes. A minimum of 10,000 gene set permutations were performed, 
and up to 1,000,000 permutations for GSEA P-values below 1×10−4.
We used the Disease Association Protein–Protein Link Evaluator package (DAPPLE; http://
www.broadinstitute.org/mpg/dapple/dapple.php) to examine evidence for protein-protein 
interaction networks connecting genes across different lipid loci. This analysis included the 
62 novel loci as well as the 95 previously known loci; we focus our discussion on pathways 
that included one or more genes from novel loci.
Cis-expression quantitative trait locus analysis
To determine whether lipid-associated SNPs might act as cis-regulators of nearby genes, we 
examined association with expression levels of 39,280 transcripts in 960 human liver 
samples, 741 human omental fat samples, and 609 human subcutaneous fat samples. Tissue 
samples were collected postmortem or during surgical resection from donors; tissue 
collection, DNA and RNA isolation, expression profiling, and genotyping were performed 
as described45. MACH was used to obtain imputed genotypes for ~2.6 million SNPs in the 
HapMap release 22 for each of the samples. We examined the correlation between each of 
the 62 new index SNPs and all transcripts within 500 kb of the SNP position, performing 
association analyses as previously described46.
Functional annotation of associated variants
We attempted to identify lipid-associated SNPs that fall in important regulatory domains. 
We initially created a list of all potentially causal variants by selecting index SNPs at loci 
identified in this study or in Teslovich et al4. We then selected any variant in strong linkage 
disequilibrium (r2 > 0.8 from 1000 Genomes or HapMap) with each index SNP. We 
compared the position of the index SNPs and their proxies to previously described 
functional marks23,24. To assess the expected overlap with functional marks, we created 
100,000 permuted sets of non-associated SNPs (see above) and evaluated permuted SNP 
lists for overlap with functional domains. We estimated a P-value for each functional 
domain as the proportion of permuted sets with an equal or greater number of loci 
overlapping functional domains (for large P-values). For small P-values we used a normal 
approximation to the empirical overlap distribution to estimate P-values.
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Association with lipid subfractions
Lipoprotein fractions for Women’s Genome Health Study (WGHS) samples (N = 23170) 
were measured using the LipoProtein-II assay (Liposcience Inc. Raleigh, NC) and 
Framingham Heart Study Offspring samples (N = 2900) were measured with the 
LipoProtein-I assay (Liposcience Inc. Raleigh, NC)47. Additional information on sub-
fraction measurements can be found in Supplementary Fig. 7. Log transformations were 
used for non-normalized traits. All models were adjusted for age, sex, and PCs. The genetic 
association analysis of WGHS used SNP genotypes imputed from the HapMap r22 CEU 
reference panel using MACH. 16,730 out of 23,170 WGHS participants were fasting for 8 
hours prior to blood draw (72.2%).
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FIGURE 1. Overlap between loci associated with different lipid traits
This Venn Diagram illustrates the number of loci that show association with multiple lipid 
traits. The number of loci primarily associated with only one trait is listed in parentheses 
after the trait name and the locus name is listed below in italics. Loci that show association 
with two or more traits are shown in the appropriate section.
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0−
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ro
m
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om
e;
M
A
F,
 m
in
or
 a
lle
le
 fr
eq
ue
nc
y;
 A
1,
 m
in
or
 a
lle
le
; A
2,
 m
ajo
r a
lle
le.
Ef
fec
t s
ize
s a
re 
giv
en
 w
ith
 re
spe
ct 
to 
the
 m
ino
r a
lle
le 
(A
1) 
in 
SD
 un
its
. F
or 
loc
i a
sso
cia
ted
 w
ith
 tw
o o
r m
ore
 tra
its
 at
 
ge
no
m
e-
w
id
e 
sig
ni
fic
an
ce
, t
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 tr
ai
t c
or
re
sp
on
di
ng
 to
 th
e 
str
on
ge
st 
P-
v
al
ue
 is
 li
ste
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fir
st.
 A
t o
ne
 lo
cu
s, 
se
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nd
ar
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tra
its
 w
er
e 
m
os
t s
tro
ng
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ss
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ia
te
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w
ith
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en
t S
N
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18
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(w
ith
in 
1 M
b o
f r
s6
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12
56
, r2
 
=
 0
.1
8).
Nat Genet. Author manuscript; available in PMC 2014 May 01.
